Last checked at 22 Aug 2017 14:13
E-THERAPEUTICS PLC
("e-therapeutics" or the "Company")
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES
Oxford, UK, 22 August 2017 - e-therapeutics plc (AIM: ETX), the computer-based drug discovery platform company, announces that it has received notifications from two of its directors that they have purchased, in aggregate, 520,000 shares in the Company at a price of 10.6 pence per share. The purchases took place today.
The number of ordinary shares purchased by each director is set out below:
Director | Number of shares purchased |
Iain Ross | 250,000 |
Ray Barlow | 270,000 |
Mr Ross purchased the shares through his self-invested personal pension (SIPP) and, following these trades, the beneficial interests of those directors in ordinary shares of ETX are as follows:
Director | Number of shares held | Percentage of issued share capital |
Iain Ross | 1,250,000 | 0.47% |
Ray Barlow | 1,100,000 | 0.41% |
The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further details:
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Iain Ross |
2 | Reason for the notification | |
a) | Position/status | Non-Executive Chairman |
b) | Initial notification/ Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | e-therapeutics plc |
b) | LEI | 21380049RHSSJXWKYT18 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of 0.1 pence
ISIN: GB00B2823H99 |
b) | Nature of the transaction | Purchase of shares through self-invested personal pension (SIPP) |
c) | Price(s) and volume(s) | 250,000 ordinary shares at a price of 10.6 pence per share |
d) | Aggregated information - Aggregated volume - Price
| N/A |
e) | Date of the transaction | 22 August 2017 |
f) | Place of the transaction | London Stock Exchange, AIM (XLON) |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Ray Barlow |
2 | Reason for the notification | |
a) | Position/status | Chief Executive Officer |
b) | Initial notification/ Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | e-therapeutics plc |
b) | LEI | 21380049RHSSJXWKYT18 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of 0.1 pence
ISIN: GB00B2823H99 |
b) | Nature of the transaction | Purchase of shares |
c) | Price(s) and volume(s) | 270,000 ordinary shares at a price of 10.6 pence per share |
d) | Aggregated information - Aggregated volume - Price
| N/A |
e) | Date of the transaction | 22 August 2017 |
f) | Place of the transaction | London Stock Exchange, AIM (XLON) |
For further information, please contact:
e-therapeutics plc Ray Barlow, Chief Executive Officer Steve Medlicott, Finance Director
| Tel: +44 (0) 1993 883 125 www.etherapeutics.co.uk
|
Numis Securities Limited Michael Meade/Freddie Barnfield(Corporate Finance) James Black (Corporate Broking)
| Tel: +44 (0) 207 260 1000 www.numis.com
|
Instinctif Partners Melanie Toyne Sewell/Alex Shaw | Tel: +44 (0) 207 457 2020 Email: e-therapeutics@instinctif.com |
About e-therapeutics plc
We are an Oxford-based company with a unique and powerful computer-based drug discovery platform and a specialised approach to network biology.
Our novel methodology and our Discovery Engine allow us to discover new and better drugs in a more efficient and effective way.
e-therapeutics is headquartered in Oxford. For more information about the Company please visit www.etherapeutics.co.uk.